Latest Acute myeloid leukemia Stories
WHITE PLAINS, N.Y. and PRINCETON, N.J., July 2, 2012 /PRNewswire/ -- The Leukemia & Lymphoma Society® (LLS) and Celator Pharmaceuticals, Inc. today announced a significant expansion of their partnership to support clinical development and potential registration of Celator's lead product candidate CPX-351 (Cytarabine:Daunorubicin) Liposome Injection for treatment of adults with acute myeloid leukemia (AML). Under the new agreement, LLS will provide $5 million in funding,...
Findings Could Yield Therapies Against These Serious Blood Diseases and Related Cancers BRONX, N.Y., July 2, 2012 /PRNewswire-USNewswire/ -- Researchers at Albert Einstein College of Medicine of Yeshiva University have found that abnormal bone marrow stem cells drive the development of myelodysplastic syndromes (MDS), serious blood diseases that are common among the elderly and that can progress to acute leukemia. The findings could lead to targeted therapies against MDS and prevent...
WHITE PLAINS, N.Y., June 27, 2012 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) was deeply saddened to learn of the death of the supremely talented Nora Ephron, from acute myelogenous leukemia (AML). Ephron had been battling myelodysplastic syndrome (MDS), which then progressed to AML. MDS is a group of diseases of the blood and bone marrow, with varying degrees of severity. Sometimes MDS can develop as a result of treatment for a different cancer. MDS is often a...
SEATTLE, June 20, 2012 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC), a company focused on translating science into novel cancer therapies, today announced that it is re-aligning its resources and re-prioritizing its product development pipeline to focus on the launch of Pixuvri in the EU and accelerate the advancement of pacritinib, CTI's recently-acquired, highly-selective JAK 2 inhibitor, into phase III clinical trials. As a result, CTI's operating...
-An estimated 10,200 Americans will die of acute myeloid leukemia (AML) in 2012, so new ways of treating the disease are needed. -This study uses a novel class of experimental drugs to halt a process that helps AML cells develop and survive. -The findings show that the agent is promising and should be considered for clinical trials testing. A novel family of experimental agents that blocks a molecule from shuttling proteins out of the cell nucleus might offer a new treatment for people...
SEATTLE, June 18, 2012 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC) today announced that the University of Washington ("UW") has begun enrolling patients in a randomized phase II study testing the combination of tosedostat with either cytarabine or decitabine for elderly patients with newly-diagnosed acute myeloid leukemia ("AML") or high-risk myelodysplastic syndrome ("MDS"). Drs. John Pagel and Elihu Estey, from the University of Washington School of...
AMSTERDAM, June 15, 2012 /PRNewswire/ -- At the 17th Congress of the European Hematology Association in Amsterdam Professor Max Topp of the University of Wuerzberg in Germany presents the impressive results with a bispecific antibody for Acute Lymphoblastic Leukemia patients. The Phase 2 dose-ranging study MT103-206 evaluated the efficacy, safety and tolerability of blinatumomab in adult patients with B-precursor Acute Lymphoblastic Leukemia who had relapsed following...
NEW YORK, June 14, 2012 /PRNewswire/ -- Citeline, the world's leading research authority on pharmaceutical clinical trials and drug intelligence, recently reviewed the results presented at the American Society of Clinical Oncology (ASCO) conference held June 1-5, 2012 in Chicago, IL. A new type of targeted therapy was of particular interest to reviewer Daphna Halpern, Citeline's Director of Oncology: Antibody-Drug Conjugates (ADC's). According to Ms. Halpern, "ADC's are looking to...
June 14, 2012, SEATTLE /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC), a company focused on translating science into novel cancer therapies, today announced that former OncoMed Pharmaceuticals executive, Steven E. Benner, M.D., M.H.S., has joined CTI as Executive Vice President and Chief Medical Officer ("CMO"), reporting to James A. Bianco, M.D., Chief Executive Officer. Dr. Benner will take over all drug development activities at the company. Dr. Benner was...
TOKYO and SAN DIEGO, June 4, 2012 /PRNewswire/ -- Astellas Pharma Inc. (Tokyo: 4503, Astellas) and Ambit Biosciences Corporation today announced the initiation of a Phase 2b open-label clinical trial of quizartinib as monotherapy in patients with relapsed and refractory acute myeloid leukemia (AML) with FLT3-ITD mutations. The trial will enroll approximately 64 adult patients (the estimated enroll of the protocol) in the United States and Europe to evaluate two oral doses of...
